Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

ence and severity of adverse events (AEs) were comparable for both treatment groups and were consistent with prior experience with Synagis. There were comparable rates of related AEs and drug discontinuations between treatment groups [related AEs: motavizumab (N=298, 9.0 percent) vs. Synagis (N=258, 7.8 percent) p=not significant (NS); discontinuations: motavizumab (N=13, 0.4 percent) vs. Synagis (N=10, 0.3 percent) p=NS]. AEs related to skin hypersensitivity reactions resulted in discontinuation of dosing in motavizumab-treated patients at low frequency (N=9, 0.3 percent). In Synagis-treated patients, there were no AEs consistent with skin hypersensitivity reactions that resulted in dosing discontinuation. The overall mortality rates were not statistically different between the two groups (N=8, 0.2 percent motavizumab and N=4, 0.1 percent Synagis); no death was considered to be related to the study drugs and there were no RSV-related deaths. Immunogenicity in the motavizumab arm was less than 1 percent and comparable to the historical Synagis rate.

The trial was a randomized, double-blind study involving 6,635 high-risk infants at 347 centers in 24 countries through three RSV seasons. Study participants comprised premature infants born at 35 weeks gestational age or less who were six months of age or younger at randomization, as well as children with CLD related to prematurity requiring medical management within the six months prior to study entry, who were 24 months of age or less at randomization.

About RSV

Each year, an estimated 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second bir
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/27/2014)... , Aug. 27, 2014 TWi ... final approval from the United States Food and ... Application (ANDA) for megestrol acetate 125mg/ml oral suspension, ... TWi is the first-to-file and under Hatch Waxman ... of marketing exclusivity.  TWi has completed the pre-launch ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a ... Terms & Agreements in Pharma, Biotech and ... The Co-development Terms and Agreements in ... understanding and unprecedented access to the co-development ... worlds leading life science companies. The ...
(Date:8/27/2014)... and MENLO PARK, Calif. , ... (OTCQB: DMPI), developer of advanced cancer therapeutics , ... 16th Annual Rodman & Renshaw Global Investment Conference, sponsored ... will take place Tuesday, September 9th at 2:55 p.m. ... the New York Palace Hotel in New ...
Breaking Medicine Technology:TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4
(Date:8/28/2014)... 28, 2014 Bleeding gums are not to ... flossing, according to the prosthodontists at the Anacapa Dental Art ... serious medical conditions, Dr. Saj Jivraj and Dr. Mamaly Reshad ... are not properly cleaning your teeth all the way down ... bleed easily,” Dr. Jivraj said. , Despite their reputations for ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 In the ... and private practices struggle with: How can the overall ... new multi-year study of the healthcare industry tackles this ... correlation between employee job satisfaction and the quality of ... can be found in “ Organizational Factors related to ...
(Date:8/28/2014)... AMTC graduate, rising star and The Voice Season ... the Top 10 finalists for Pepsi’s Southern Original . He’s ... for his mentor and coach from The Voice and country music ... slot on Thursday, August 28th at 9:00 pm at Tootsie’s at ... will perform at the Gulf Coast Jam main stage on Sunday, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Top ... many web hosting companies and announces Bluehost, HostMonster ... recommended suppliers for the webmasters worldwide who want ... rates. , As the world’s most popular server-side ... and many other general-purpose programs. It is now ...
(Date:8/28/2014)... August 28, 2014 Alpine, NJ resident ... of his team, Zebras In Tiaras, to benefit the ... be held October 26, 2014 in Foley Square, New ... immunodeficiency community. Primary immunodeficiency diseases (PI) are a group ... which part of the body’s immune system is missing ...
Breaking Medicine News(10 mins):Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 2Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 3Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 4Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 5Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:Rising Star Brandon Chase Named Finalist in Pepsi Southern Original Contest 2
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
... for Patient-Provider Decision MakingFurther Action Needed to Ensure ... Senate today improved on a comparative effectiveness research ... $1.1 billion dollar research effort on clinical effectiveness," ... of the National Alliance for Hispanic Health, the ...
... Ringling Bros.(R) Conservation and Breeding ProgramVIENNA, Va., Jan. 27 ... Elephant Conservation (R) proudly announces the ... twenty-second birth in what has proven to be the most ... importantly, this is the first calf in the Ringling ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) ... the market closes, it will report results for the ... February 24, 2009, at 9:00 a.m. Central Time, Healthcare ... results, quarterly activities,general operations of the Company and industry ...
... has completed a new study on uric acid and C8 and ... increased uric acid is associated with higher levels of C8 and ... can cause an increase in uric acid.The Science Panel team recently ... (also known as PFOA) and C8S (also known as PFOS) in ...
... St. Jude Children,s Research Hospital and the Children,s Oncology ... leukemia (ALL) scores of inherited genetic variations that clinicians ... more effective chemotherapy for this cancer. ... rates for ALL exceed 80 percent, patient responses vary ...
Cached Medicine News:Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 4Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 5Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:C8 Science Panel Completes Uric Acid Study 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: